Hioki T, Sugimura Y
Department of Urology, Aichi Cancer Center.
Hinyokika Kiyo. 1999 Aug;45(8):577-81.
Detection of circulating cancer cells in peripheral blood may improve cancer staging and monitoring. This study was undertaken to investigate the clinical implications of detection of circulating cancer cells in renal cancer patients. Cytokeratin-19 (CK19) mRNA was amplified by nested reverse transcription-polymerase chain reaction (RT-PCR) in the peripheral blood of 33 healthy volunteers and 19 patients with renal cell carcinoma. The detection limit of the method was 10 cancer cells in 10(7) peripheral blood mononuclear cells. The positive detection rate was 47% for renal cancer patients and 9% for healthy volunteers. The number of patients expressing CK19 mRNA in each clinical stage was 0 out of 3 patients in stage 1; 2 out of 8 (25%) in stage 2; 3 out of 4 (75%) in stage 3; 4 out 4 (100%) in stage 4. A significant correlation was seen between CK19 mRNA expression and clinical stage (p = 0.0023). This method may be useful for early detection of micrometastasis, and facilitate the design of better therapeutic strategies for the treatment of renal cancer patients.
检测外周血中循环癌细胞可能会改善癌症分期和监测。本研究旨在探讨检测肾癌患者循环癌细胞的临床意义。采用巢式逆转录聚合酶链反应(RT-PCR)扩增33名健康志愿者和19名肾细胞癌患者外周血中的细胞角蛋白19(CK19)mRNA。该方法的检测限为10⁷个外周血单个核细胞中有10个癌细胞。肾癌患者的阳性检出率为47%,健康志愿者为9%。各临床分期中表达CK19 mRNA的患者数量为:Ⅰ期3例患者中0例;Ⅱ期8例中有2例(25%);Ⅲ期4例中有3例(75%);Ⅳ期4例中有4例(100%)。CK19 mRNA表达与临床分期之间存在显著相关性(p = 0.0023)。该方法可能有助于早期检测微转移,并有助于为肾癌患者设计更好的治疗策略。